Subscribe
Our secret buy sider says retail investors have time on their side.
Can impressive investment tally with generous dividend growth?
Now focussed fully on pharma, GSK has competing demands on its cash
The private equity trust is in better health than its discount would suggest.
US blue chips CME Group, Kraft Heinz and Gilead Sciences have important advantages
Shares look cheap compared to platform and software sum of parts
Shares in this payments business fell 75 per cent from IPO but now don't look expensive.
Short-term earnings are buoyant but are green plans enough?
Recession resilient businesses are rightly prized but are they fairly valued?
Our secret buyside analyst runs the rule over dividend payers for the tough economic climate.
